Correlation Between Blueprint Medicines and Ocuphire Pharma
Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and Ocuphire Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and Ocuphire Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Blueprint Medicines Corp and Ocuphire Pharma, you can compare the effects of market volatilities on Blueprint Medicines and Ocuphire Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of Ocuphire Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and Ocuphire Pharma.
Diversification Opportunities for Blueprint Medicines and Ocuphire Pharma
-0.09 | Correlation Coefficient |
Good diversification
The 3 months correlation between Blueprint and Ocuphire is -0.09. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and Ocuphire Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ocuphire Pharma and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with Ocuphire Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ocuphire Pharma has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and Ocuphire Pharma go up and down completely randomly.
Pair Corralation between Blueprint Medicines and Ocuphire Pharma
Given the investment horizon of 90 days Blueprint Medicines Corp is expected to generate 0.72 times more return on investment than Ocuphire Pharma. However, Blueprint Medicines Corp is 1.38 times less risky than Ocuphire Pharma. It trades about 0.07 of its potential returns per unit of risk. Ocuphire Pharma is currently generating about -0.03 per unit of risk. If you would invest 4,429 in Blueprint Medicines Corp on September 1, 2024 and sell it today you would earn a total of 5,209 from holding Blueprint Medicines Corp or generate 117.61% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 94.73% |
| Values | Daily Returns |
Blueprint Medicines Corp vs. Ocuphire Pharma
Performance |
| Timeline |
| Blueprint Medicines Corp |
| Ocuphire Pharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Blueprint Medicines and Ocuphire Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Blueprint Medicines and Ocuphire Pharma
The main advantage of trading using opposite Blueprint Medicines and Ocuphire Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, Ocuphire Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ocuphire Pharma will offset losses from the drop in Ocuphire Pharma's long position.| Blueprint Medicines vs. Terns Pharmaceuticals | Blueprint Medicines vs. Amylyx Pharmaceuticals | Blueprint Medicines vs. Acumen Pharmaceuticals | Blueprint Medicines vs. Inozyme Pharma |
| Ocuphire Pharma vs. Reviva Pharmaceuticals Holdings | Ocuphire Pharma vs. Protalix Biotherapeutics | Ocuphire Pharma vs. Eyepoint Pharmaceuticals | Ocuphire Pharma vs. Sellas Life Sciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Complementary Tools
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |